摘要
糖尿病已经成为人类的第三大疾病死亡原因,中国目前患者达到9200万,居世界第一位,并且随着肥胖和坐卧式生活习惯的流行,糖尿病的发病率将不断上升。其中2型糖尿病肾病是糖尿病的重要并发症之一,成为患者重要的死亡原因之一,然而目前尚未有效治2型糖尿病肾病疗药物。
本文研究以一种合理的2型糖尿病肾病大鼠模型建立方法开始。其中通过两种同的2型糖尿病肾病的造模方法,模型建立8周时间,比较大鼠血糖水平、胰岛素抵抗状态和肾功能指标。实验结果表明,高糖高脂饲料喂养4周后腹腔注射小剂量链脲佐菌素观察8周其血糖达到27.95 mmol·l-1显著超过正常组的5.68 mmol·l-1,并且尿微量白蛋白水平达到129.73μg·l-1显著超过正常组的24.01μg·l-1,证明此种方法可以建立稳定的2型糖尿病肾病大鼠模型,并且操作简单、人为影响较少。
另外,通过利用罗布麻提取物对2型糖尿病大鼠模型进行干预后,大鼠模型的高血糖水平并没有明显差异,但是治疗组肾功能损伤呈剂量依赖型恢复。实验结果显示尿微量白蛋白降低76.2%,表明罗布麻提取物起到显著的保护肾功能作用。
然后对血清中的糖基化水平、氧化应激水平、肿瘤坏死因子-α、生长转化因子-β细胞因子进行研究,实验结果显示糖基化水平、肿瘤坏死因子-α、生长转化因子-β分别降低48.2%、63.1%和51.2%,并且氧化应激水平明显降低。提示罗布麻提取物通过降低糖基化和氧化应激保护肾功能损
Diabetes is the third in the diseases which induces died. Nowadays there are 9,200,000 diabetes in China, China is the NO.1 diabetes in the world. What's more, fat and sitting and lying style habits becomes more and more popular, The incidence of diabetes will continue to rise. Type 2 diabetic nephropathy is one of the most complications, whereas, there isn't effective drugs.
In this paper, establish a reasonable model of type 2 diabetic nephropathy methods rats, Which are two different type 2 diabetic nephropathy in the modeling method, model 8 weeks to compare the blood glucose levels, insulin resistance and renal function. The results showed that the blood glucose and microalbuminuria in the group of high glucose and high fat diet for 4 weeks after the intraperitoneal injection of low dose streptozotocin is 27.95 mmol·l-1 and 129.73μg·l-1. That this method can establish a stable type 2 diabetic nephropathy rat model, and simple, less human impact.
In addition, through the use of Apocynum extract on rat model of type 2 diabetes after the intervention, rats model of high blood sugar levels and no significant difference, but the treatment of renal dysfunction in a dose-dependent recovery. The results showed 76.2% reduction of urinary albumin, indicating that Apocynum extracts play a significant protection of renal function.
Then serum levels of glycosylation, oxidative stress, tumor necrosis factor-a, transforming growth factor-βcytokine researched. Experimental results showed that glycosylation, tumor necrosis factor-a, transforming growth factor-βdecreased by 48.2%,63.1% and 51.2%, and significantly lower levels of oxidative stress. Tips Apocynum extract by reducing glycation and oxidative stress protection of renal function impairment.
引文
[1]Wysowski DK, Armstrong G, Governale L. Rapid increase in the use of oraln antidiabetic drugs in the United States 1990-2001 [J]. Diabetes Care,2003,26(6):1852-1855.
[2]Wenying Yang, Juming Lu, Jianping Weng, et al. Prevalence of diabetes among man and women in China[J]. The new England journal of medicine,2010,362(12):1090-1101.
[3]左风(摘译).罗布麻叶水提取物对大鼠高胆固醇血症的作用[J].国外医学·中医中药分册,1999.21(1)：51-52
[4]仝燕(摘译).罗布麻及大叶白麻叶中黄酮化合物的含量及其脂质过氧化抑制作用[J].国外医学·中医中药分册,1996,18(1)：49
[5]贺玉琢(摘译).罗布麻叶提取物的降压作用(1)[J].国外医学·中医中药分册,2005,27,(3)：176-177.
[6]贺玉琢(摘译).罗布麻叶提取物的降压作用(2)[J].国外医学·中医中药分册,2005,27(3)：177-178
[7]Kim D W, Yokozawa T, Hattori M, et al. Luobuma leaf inhibits oxidation of low-denstiy lipoprotein in cholesterol-fed rats [J]. Foreign Med:Tridit Chin Med(国外医学：中医中药分册),1999,21(4)：18.
[8]Kim D, Yokozaw T, Hattor M, et al. Effects of aqueous extracts of Apocynum venetum leaves on Spotanarously hypertensive, renal hypertensive and NaCl-fed-hypertensive rats[J]. J Ethnopharmacol,2000,72 (1-2):53-59.
[9]Kwan CY, Zhang WB, Nishibe S, Seo S. A novel in vitro endothelium-dependent vascular relaxant effect of Apocynum venetum leaf extract[J]. Clin Exp Pharmacol Physiol.2005 Sep;32(9):789-95.
[10]滕香宇.新型胰岛素类似物的研究进展[J].世界临床药物,2004,25(12)：714-717.
[11]邹大进.肠促胰岛素在2型糖尿病治疗中的生理学和药理学特点[J].中国糖尿病杂志,2009,1 7(3)：28-29.
[12]A.Mari, L. Nielsen, N. Nanayakkara, et al. Mathematical Modeling Shows Exenatide Improved P-Cell Function in Patients with Type 2 Diabetes Treated with Metformin or Metformin and a Sulfonylurea[J]. Horm Metab Res 2006; 38(12):834-844.
[13]Robert C. Turner, Carole A. Cull, Valeria Frighi, et al. Glycemic Control With Diet, Sulfonylurea, Metformin, or Insulin in Patients With Type 2 Diabetes Mellitus. Progressive Requirement for Multiple Therapies (UKPDS 49) [J]. JAMA.1999; 281:2005-2012.
[14]Mosbach K, Nicholls I A, Ramstrom O. Use of molecularly imprinted polymers for stereo and region-selective synthesis [P]. PCT Patent, WO 9414835.1995-11-14.
[15]Steven E. Nissen, Kathy Wolski. Effect of Rosiglitazone on the Risk of Myocardial Infarction and Death from Cardiovascular Causes[J]. The new England journal of medicine, 2007,24(356):2457-2471.
[16]Robert C. Turner, Carole A. Cull, Valeria Frighi, et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study [J]. BMJ.2000; 321:405-412.
[17]John Buse, Henry Ginsberg, George Bakris, et al. Primary Prevention of Cardiovascular Diseases in People With Diabetes Mellitus[J]. Circulation,2007,115:114-126.
[18]Gao Ping, JIA Ruhan. Establishment of Rat Model of Type 2 Diabetic Nephropathy[J]. Chinese Journal of Integrated Traditional and Western Nephropathy 2007,8(6):316-319.
[19]宋恩峰,刘晶晶,贾汝汉等.2型糖尿病肾病大鼠模型制备研究[J].实用医学杂志,2007,24(18)：2840-2842.
[20]查冬青,吴小燕,徐联芳等.两种2型糖尿病肾病动物模型的比较[J].中国比较医学杂志,2006,27(2)：253-256.
[21]Zhao Meimi, LI Zhi, Teng Zan, et al. Repeated oral treatment with polysaccharide sulfate reduces insulin resistance and dyslipidemia in diabetic dyslipidemic rat model[J]. Acta Pharmaceutica Sinica 2007,42(5):488-491.
[22]翁建平.糖尿病肾病的诊断和治疗[J].临床内科杂志,2005,22(3)：150-153.
[23]Wang Rongrong, XIE Lin, WU Xiaoye, et al. Effect of gingko bfloba extract on liver from experimental type 2 diabetic rats [J]. Chinese Journal of Pathophysiology 2007,23(3): 566-569.
[24]陈宇.糖尿病肾血管病变及其发病机理[J].临床内科杂志,1997,14(3)：119-120.
[25]殴阳涓,姜傥.肾脏的损伤性诊断[J].中华检验医学杂志,2005,28(8)：877-879.
[26]Jeannie W C Messent, Thomas G Elliott, Ronald D Hill, et al. Prognostic significance of microalbuminuria in insulin-dependent diabetes mellitus:A twenty-three year follow-up study[J]. Kidney International (1992) 41,836-839; doi:10.1038/ki.1992.128.
[27]Josephine M F, Mark E C, Matthew D O, et al. Role of Advanced Glycation End Products in Diabetic Nephropathy[J]. J Am Soc Nephrol 2003,14:S254-S258.
[28]Sandei N, Michiko M, Chisako C, et al. Flavonid content in Apocynum and Poacnum leaves and lipid-peroidation inhibiting effect of flavonoids[J]. Nat Med,1994,48 (4): 322-323.
[29]王彬尧,王长谦.甘油三酯与冠心病的关系[J].国外医学,2000,27(2)：79-81.
[30]刘静,赵东.低密度脂蛋白胆固醇与心血管病发病关系的前瞻性研究[J].中华心血管病杂志.29(9)：561-565.
[31]Lane JT. Microalbuminuria as a marker of cardiovascular and renal risk in type 2 diabetes mellitus:a temporal perspective[J]. Am J Physical Renal Physiol,2004,286:442-450.
[32]陈小瑞,申竹芳.非酶糖基化终末产物与糖尿病肾脏并发症[J].中国临床药理学杂志,2003,19(3)：215-219.
[33]R. Singh, A. Barden, T. Mori, et al. Advanced glycation end-products:a review[J]. Diabetologia, (2001)44:129-146.
[34]Juan J, Frasncisco Milena, Carmen Mora, et al. Tumor necrosis factor-a gene expression in diabetic nephropathy:Relationship with urinary albumin excretion and effect of angiotensin-converting enzyme inhibition[J]. Kidney International (2005) 68, S98-SI02.
[35]Sheldon Chen, Belinda Jim, Fuad N. Diabetic nephropathy and transforming growth factor-β:transforming our view of glomerulosclerosis and fibrosis build-up[J]. Seminars in Nephrology,2003,23(6):532-543.
[36]杨新波,黄正明,陈红艳等.罗布麻叶提取物对四氧嘧啶诱发的糖尿病小鼠肾功能降低的影响[J].解放军药学学报,2008,24(5)：408-41 1.
[37]J W Baynes and S R Thorpe. Role of oxidative stress in diabetic complications:a new perspective on an old paradigm[J]. diabetes,2008,1:383-5
[38]R. Singh, A. Barden, T.mori, et al. Advanced glycation end-products and the kidney[J].Am J Physiol Renal Physiol,289:F645-F659,2005.
[39]李治平.非酶糖基化终末产物与糖尿病视网膜病变.国外医学.眼科学分册,2001；25(3)：173-176.
[40]Tuschida K, Makita Z, Yamagishi S, et al. Suppression of transforming growth factor beta and vascular endothelial growth factor in diabetic nephropathy in rats by a novel advanced glycation end-products inhibitor OPB-9195. Diabelogia,1999,42:577-588.
[41]T Yamamoto, T Nakamura, N Noble, et al. Expression of transforming growth factor beta is elevated in human and experiment diabetic nephropathy [J]. PNAS,1993,90(5):1814-1818.
[42]J Navarro, C Mora. The role of TNF-a in diabetic nephropathy:Pathogenic and therapeutic implications[J]. CGFR,2006,17(6):441-450.
[43]黄淑妍,刘雪芳,陈澍等.缬沙坦对糖尿病大鼠糖代谢及超氧化物歧化酶、丙二醛的影响.实用医学杂志,2007,23(3)：342-343
